肝硬化合并慢性肾脏病患者中的急性肾损伤:HRS-HARMONY联盟研究结果
基于HRS-HARMONY联盟11个医院网络2057例肝硬化合并急性肾损伤患者,比较单纯急性肾损伤与慢性肾脏病基础上急性肾损伤的结局。慢性肾脏病基础上急性肾损伤组90天死亡率更低(亚风险比0.72,95%CI 0.61-0.87),可能因单纯急性肾损伤组肝功能更差。
要点
- 肝硬化急性肾损伤患者中,30%为慢性肾脏病基础上急性肾损伤。
- 慢性肾脏病基础上急性肾损伤组90天死亡风险低于单纯急性肾损伤组(亚风险比0.72)。
- 单纯急性肾损伤组肝功能指标更差,ICU入住率和肾脏替代治疗使用率更高。
核心结论
- 在住院的肝硬化合并急性肾损伤患者中,慢性肾脏病基础上急性肾损伤与较低的90天死亡率相关。
- 这可能由单纯急性肾损伤组更差的肝功能参数对短期结局的影响所致。
- 需要进一步研究肝硬化中急慢性肾脏病之间复杂的相互作用。
研究设计与样本
- HRS-HARMONY联盟多中心研究,共纳入11个医院网络2057例肝硬化合并急性肾损伤患者,其中70%为单纯急性肾损伤,30%为慢性肾脏病基础上急性肾损伤。
- 主要结局为90天死亡率,采用Fine和Gray分析,并将移植作为竞争风险,进行未调整和调整分析。
主要发现
- 慢性肾脏病基础上急性肾损伤组入院肌酐中位数2.25(四分位距1.7-3.2)mg/dL vs 单纯急性肾损伤组1.83(1.38-2.58)mg/dL,峰值肌酐2.79(2.12-4)mg/dL vs 2.42(1.85-3.50)mg/dL。
- 慢性肾脏病基础上急性肾损伤组总胆红素中位数1.5(四分位距0.7-3.1)mg/dL vs 单纯急性肾损伤组3.4(1.5-9.3)mg/dL,国际标准化比值1.4(1.2-1.8)vs 1.7(1.39-2.2),P均<.001。
- 慢性肾脏病基础上急性肾损伤组代谢功能障碍相关脂肪性肝病肝硬化比例31% vs 单纯急性肾损伤组17%,酒精相关性肝病比例26% vs 45%,P均<.001。
- 单纯急性肾损伤组未调整死亡率39% vs 慢性肾脏病基础上急性肾损伤组30%,ICU入住率52% vs 35%(P均<.001),肾脏替代治疗使用率20% vs 15%(P=.005)。
- 调整年龄、种族、性别、移植等待状态和终末期肝病模型-钠评分后,慢性肾脏病基础上急性肾损伤与较低的90天死亡率相关(亚风险比0.72,95%CI 0.61-0.87)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic kidney disease (CKD) frequency is increasing in patients with cirrhosis and these individuals often experience acute kidney injury (AKI). Direct comparisons of outcomes between AKI-only versus AKI on CKD (AoCKD) among patients with cirrhosis are not well described. METHODS: A total of 2057 patients with cirrhosis and AKI across 11 hospital networks from the HRS-HARMONY consortium were analyzed (70% AKI-only and 30% AoCKD). The primary outcome was unadjusted and adjusted 90-day mortality, with transplant as a competing risk, using Fine and Gray analysis. RESULTS: Compared with patients with AKI-only, patients with AoCKD had higher median admission creatinine (2.25 [interquartile range, 1.7-3.2] vs 1.83 [1.38-2.58] mg/dL) and peak creatinine (2.79 [2.12-4] vs 2.42 [1.85-3.50] mg/dL) but better liver function parameters (total bilirubin 1.5 [interquartile range, 0.7-3.1] vs 3.4 [1.5-9.3] mg/dL; and international normalized ratio 1.4 [interquartile range, 1.2-1.8] vs 1.7 [1.39-2.2]; P < .001 for all). Patients with AoCKD were more likely to have metabolic dysfunction associated steatotic liver disease cirrhosis (31% vs 17%) and less likely to have alcohol-associated liver disease (26% vs 45%; P < .001 for both). Patients with AKI-only had higher unadjusted mortality (39% vs 30%), rate of intensive care unit admission (52% vs 35%; P < .001 for both), and use of renal-replacement therapy (20% vs 15%; P = .005). After adjusting for age, race, sex, transplant listing status, and Model for End-Stage Liver Disease-Sodium score, AoCKD was associated with a lower 90-day mortality compared with AKI-only (subhazard ratio, 0.72; 95% confidence interval, 0.61-0.87). CONCLUSIONS: In hospitalized patients with AKI and cirrhosis, AoCKD was associated with lower 90-day mortality compared with AKI-only. This may be caused by the impact of worse liver function parameters in the AKI-only group on short-term outcomes. Further study of the complicated interplay between acute and chronic kidney disease in cirrhosis is needed.
引用
- St Hillien SA, Robinson JE, Ouyang T, et al. Acute Kidney Injury in Patients With Cirrhosis and Chronic Kidney Disease: Results From the HRS-HARMONY Consortium. Clin Gastroenterol Hepatol. 2024. PMID: 39675402. doi:10.1016/j.cgh.2024.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。